NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency.
user service
Show more
See More
NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency.
user service
Show more
See More
NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency. The NeoChord Artificial Chordae Delivery System, Model DS1000 , meets the essential requirements referred to in Article 3 of the MDD 93/42/EEC and is labeled with the CE marking ...
user service
Show more
See More
NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency.The NeoChord Artificial Chordae Delivery System, Model DS1000, meets the essential requirements referred to in Article 3 of the MDD 93/42/EEC and is labeled with the CE marking of conformity.
user service
Show more
See More
NeoChord is a medical device company that has developed a proprietary device that allows mitral valve repair to be performed on a beating heart through a 2 to 3 inch incision between the ribs in patients with severe, degenerative mitral valve regurgitation.
Employees: 6
Founding Date: 2007
Founded: 2007
Type: Private
user service
Show more
See More
Aug 14, 2018 . In November 2016, David H. Adams, MD, performed the first NeoChord procedure in the United States, in a trial exploring the efficacy of beating-heart mitral valve repair, without the use of cardiopulmonary bypass, through a minithoracotomy. A clinical study is ongoing within the United States to evaluate the use of the NeoChord DS1000.
user service
Show more
See More
Jan 08, 2013 . Tech Update: NeoChord Mitral Valve Repair Device Gets CE Mark. By Adam Pick on January 8, 2013. As we continue to monitor the newest technologies enhancing valvular therapy, I though you might like to know that the NeoChord mitral valve repair system recently received a CE mark for use in Europe. This unique device, which is not FDA approved in ...
user service
Show more
See More
Jan 29, 2013 . The placement of at least one NeoChord using the DS1000 System AND a reduction in mitral regurgitation <= 2+ at the time of the procedure AND maintained MR reduction of <= 2+ at 30 days. Secondary Outcome Measures : Procedural Safety [ Time Frame: 30 days ] the rate of Major Adverse Events (MAE) defined as a combined endpoint of: death, MI ...
user service
Show more
See More
Mar 24, 2017 . The NeoChord DS1000 Device. 4 years ago. NeoChord. Upload, livestream, and create your own videos, all in HD. Join Vimeo.
Views: 484
Show more
See More
Oct 16, 2009 . Digital animation of beating-heart, sternal-sparing implantation of artificial chordae tendineae enabled by NeoChord's surgical device -- a minimally-invasiv...
Show more
See More
Contact Email info@NeoChord.com Phone Number 952-698-7800 NeoChord is a medical device company that has developed a proprietary device that allows mitral valve repair to be performed on a beating heart through a 2 to 3-inch incision between the ribs in patients with severe, degenerative mitral valve regurgitation.
user service
Show more
See More
Due to a considerably less invasive procedure, the NeoChord surgical method is predicted to reduce mitral valve surgery hospital stays from eight days to two. This surgical method already shows an acute procedure success rate, which is greater …
user service
Show more
See More
Jun 17, 2016 . Randomized Trial of the NeoChord DS1000 System Versus Open Surgical Repair (ReChord) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by …
user service
Show more
See More
Nov 14, 2018 . NeoChord raises $21m. November 14, 2018 By Fink Densford. NeoChord has raised $20.6 million in a new round of equity financing, according to a recently posted SEC filing. The St. Louis Park, Minn ...
user service
Show more
See More
Oct 28, 2016 . NeoChord Again Awarded NUB Status 1 In Germany. 2/10/2016. NeoChord Appoints Lori Adels, Ph.D. As Vice President Of Clinical Affairs, Regulatory And Quality. 10/20/2015. NeoChord Bags $12.6 Million for Mitral Valve Repair Tool That Works Without Stopping the Heart. 5/26/2015. NeoChord Appoints David Chung As President And CEO. …
user service
Show more
See More
Nov 06, 2018 . NeoChord said yesterday it closed a $25 million Series D equity financing round to help support its mitral valve repair system intended to treat mitral valve regurgitation.. The round was led by U ...
user service
Show more
See More
Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque. Font Size. 50% 75% 100% 125% 150% 175% 200% 300% 400%. Text Edge Style. None Raised Depressed Uniform Dropshadow. Font Family. Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual …
Show more
See More
The NeoChord procedure allows patients an alternative to still undergo a quality repair without enduring the rigors of traditional treatment via open-chest …
Show more
See More
We are currently recruiting for a Sr. Manager, End User Services to join the Viking Technology team at our corporate headquarters office in Woodland Hills, …
Show more
See More
Who are we? NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company’s flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.
The NeoChord Artificial Chordae Delivery System is a beating heart procedure, echo-guided treatment option for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. This opens in a new window.
Tech Update: NeoChord Mitral Valve Repair Device Gets CE Mark. This unique device, which is not FDA approved in America, enables minimally invasive implantation of artificial chordae using a catheter-based approach. If you did not know, the chordae support the mitral valve leaflets as they open-and-close to move the blood through your heart.
The first 50 patients of the TACT study are scheduled to undergo the NeoChord procedure during the first three months of this year. Dr. Giovanni Speziali, one of the proctors of the study from the University of Pittsburgh Medical Center, stated: